Abstract
To review new pharmacologic therapies and technologies relevant to the management of diabetes and its complications. New treatment options for diabetes, made available through research efforts during the past 2 decades, are discussed. Several new drugs and drug classes for the management of diabetes are under development, including the incretin mimetic agents (exenatide, dipeptidyl peptidase 4 inhibitors, and glucagon-like peptide 1 analogues), the amylin analogue pramlintide, the cannabinoid-1 receptor antagonist rimonabant, the mixed peroxisome proliferator-activated receptor agonists muraglitazar and tesaglitazar, the inhaled insulin preparation Exubera, and the insulin analogues (insulin glulisine and insulin detemir). New drugs and technologic advances being made available will help achieve the goals of treating patients with diabetes to all the appropriate metabolic targets. Many other agents that act on fundamental abnormalities such as energy imbalance, inflammation, and vascular biologic conditions are in very early stages of development but are likely to become available during the next 5 to 10 years.
References
Jul 5, 2003·The Annals of Pharmacotherapy·Erika L Kleppinger, Eva M Vivian
Oct 28, 2003·Diabetes Care·Christian WeyerDavid G Maggs
Nov 18, 2003·Diabetes, Obesity & Metabolism·P HollanderC Weyer
Oct 23, 2004·Diabetic Medicine : a Journal of the British Diabetic Association·R E RatnerO G Kolterman
Oct 27, 2004·Diabetes Care·John B BuseUNKNOWN Exenatide-113 Clinical Study Group
Nov 25, 2004·Diabetes Care·Bo AhrénAnja Schweizer
Feb 11, 2005·American Journal of Health-system Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists·Orville G KoltermanAlain D Baron
Mar 23, 2005·Regulatory Peptides·Michael A Nauck, Juris J Meier
Apr 2, 2005·Journal of Medicinal Chemistry·Kun LiuA Brian Jones
Apr 14, 2005·The Annals of Pharmacotherapy·Peggy Soule Odegard, Kam L Capoccia
Apr 20, 2005·Lancet·Luc F Van GaalUNKNOWN RIO-Europe Study Group
Apr 22, 2005·Diabetologia·I ChapmanM Horowitz
Apr 28, 2005·Diabetes Care·David M KendallAlain D Baron
Apr 28, 2005·Diabetes Care·Ralph A DeFronzoAlain D Baron
May 14, 2005·Experimental and Clinical Endocrinology & Diabetes : Official Journal, German Society of Endocrinology [and] German Diabetes Association·R RatnerC Weyer
Jun 7, 2005·Expert Opinion on Pharmacotherapy·Satish K GargHeather Ulrich
Jun 7, 2005·Life Sciences·Mauro A M CaraiGian Luigi Gessa
Jun 25, 2005·Diabetic Medicine : a Journal of the British Diabetic Association·T R PieberV Grill
Oct 22, 2005·JAMA : the Journal of the American Medical Association·Steven E NissenEric J Topol
Citations
Apr 26, 2007·Angiogenesis·Carla CostaRaquel Soares
Jun 6, 2007·Current Diabetes Reports·William T Cefalu
Mar 31, 2007·International Journal of Clinical Practice·J Tibaldi, R E Rakel
Feb 19, 2008·Osteopathic Medicine and Primary Care·Michael Valitutto
Apr 7, 2011·Journal of Multidisciplinary Healthcare·Bridget R Levich
Mar 6, 2007·Diabetes Care·Richard W GrantDavid M Nathan
Jul 14, 2007·European Journal of Pharmacology·Sherin Y BoctorCharles P France
Feb 27, 2007·Diabetes Research and Clinical Practice·Franziska P BusseMichael Stumvoll
Sep 11, 2008·Clinical Cardiology·Andrew ZinnArthur Schwartzbard
Mar 30, 2007·Diabetes Care·Paul S JellingerUNKNOWN ACE/AACE Outpatient Glycemic Control Implementation Task Force